Uncategorized

ENHERTU® Demonstrated Statistically Significant & Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial

Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard of care chemotherapy in the primary trial population of patients with HR positive, HER2 low metastatic breast cancer following one or more lines of endocrine therapy.

ENHERTU® Demonstrated Statistically Significant & Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial Read More »

AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)

AriBio Co., Ltd. announced authorisation from the European Medicines Agency for POLARIS-AD, a global, phase 3, early Alzheimer’s disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency on the Clinical Trial Authorisation of POLARIS-AD.

AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD) Read More »

Spectrum Dynamics Medical and Hermes Medical Solutions Enter Into Partnership to Offer Integrated Solution of the Hermia Software With the VERITON-CT Scanner

Spectrum Dynamic’s customers will benefit from Hermia’s best-in-class nuclear medicine and dosimetry software applications to fully leverage the unique technology and image quality of VERITON-CT scans.

Spectrum Dynamics Medical and Hermes Medical Solutions Enter Into Partnership to Offer Integrated Solution of the Hermia Software With the VERITON-CT Scanner Read More »

Scroll to Top